Israel Englander Vista Gen Therapeutics, Inc. Transaction History

Millennium Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.09 - $4.8 $67,240 - $3.59 Million	-747,117 Reduced 87.42%	107,494 $11,000
Q3 2022 Nov 14, 2022	SELL	$0.14 - $4.8 $2,568 - $88,070	-18,348 Reduced 2.1%	854,611 $130,000
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.73 $323,246 - $635,473	-367,326 Reduced 29.62%	872,959 $768,000
Q1 2022 May 16, 2022	BUY	$1.14 - $2.09 $1.4 Million - $2.57 Million	1,229,705 Added 11622.92%	1,240,285 $1.54 Million
Q4 2021 Feb 14, 2022	SELL	$1.67 - $2.76 $726,045 - $1.2 Million	-434,758 Reduced 97.62%	10,580 $21,000
Q3 2021 Nov 15, 2021	BUY	$2.62 - $3.45 $703,813 - $926,776	268,631 Added 152.02%	445,338 $1.22 Million
Q2 2021 Aug 16, 2021	SELL	$1.96 - $3.15 $2.39 Million - $3.84 Million	-1,219,682 Reduced 87.35%	176,707 $557,000
Q1 2021 May 17, 2021	BUY	$1.89 - $2.96 $1.16 Million - $1.82 Million	614,704 Added 78.64%	1,396,389 $2.97 Million
Q4 2020 Feb 16, 2021	BUY	$0.65 - $1.94 $508,095 - $1.52 Million	781,685 New	781,685 $1.52 Million
Q1 2019 May 14, 2019	SELL	$1.1 - $1.76 $20,485 - $32,776	-18,623 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.28 - $2.24 $23,837 - $41,715	18,623 New	18,623 $28,000

27.1K

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $517M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.